Mood stabilizer selection in bipolar disorder is one of the highest-stakes prescribing decisions in psychiatry, because the choice will likely persist for years and the cost of getting it wrong is high — both in terms of patient burden and in terms of the disease trajectory. This concept synthesizes the prior six into clinical reasoning.
- Class
- Decision framework
- Mechanism
- Selection driven by: phase of illness, predominant polarity, sex/childbearing status, comorbidities, prior response, suicide history, monitoring capacity
- FDA indications
- Frameworks for: acute mania vs depression vs maintenance; bipolar I vs II; pregnancy planning; rapid cycling; treatment-resistant cases
Decision-tree concept — synthesizing the prior 6 concepts into clinical reasoning. Not a single drug card but a framework for the V4 (Living Encounter) clinical integration.
The first split is phase of illness. Acute mania calls for fast-acting antimanic agents — lithium, valproate, or an antipsychotic (often olanzapine, risperidone, or quetiapine), frequently in combination for severe presentations. Bipolar depression calls for agents with depression efficacy — quetiapine, lurasidone, cariprazine, or lamotrigine. The bipolar depression options are different from MDD options because antidepressant monotherapy is contraindicated in bipolar disorder — risk of induction of mania, rapid cycling, or destabilization. Maintenance calls for the long-haul agent: lithium remains the gold standard, particularly for patients with suicide history; lamotrigine for predominantly depressive bipolar II; combinations for patients with both poles.
The second split is patient factors. Women of childbearing potential: avoid valproate; consider lithium with planning, lamotrigine, or atypicals with safer pregnancy profiles. Suicide history: lithium is the unique anti-suicidal agent. Metabolic concerns: lamotrigine, lurasidone, cariprazine over quetiapine or olanzapine. Cognitive concerns: lamotrigine, often. Severe acute mania with psychosis: an antipsychotic is usually part of the regimen.
Mood stabilizer selection is a matching problem — the agent is chosen to fit the predominant pole, the cycling pattern, and the patient's safety constraints.
Mechanism note: Selection logic: match the agent to the predominant pole and cycling pattern, then filter by safety constraints — childbearing potential, renal/thyroid status, metabolic risk.
Combination strategies are common and often appropriate. Lithium plus lamotrigine — antimanic plus depression prophylaxis — covers both poles in a complementary way. Mood stabilizer plus atypical antipsychotic for severe mania uses faster onset and broader mechanism. Mood stabilizer plus atypical for refractory cases broadens the receptor coverage when monotherapy has failed.
The shared rule: avoid antidepressant monotherapy in any bipolar disorder. If a depressive episode requires antidepressant addition, do so only after a mood stabilizer is established, monitor for switching to mania, and consider stopping the antidepressant once the episode resolves.
For the bipolar patient, the most important treatment decision is the maintenance choice — the one they will live with for years. Choose it deliberately, in shared decision-making, with a clear plan for monitoring and an honest discussion of trade-offs.